Tagged with generics,

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Spain Enrique Ordieres, president of Cinfa Group, the leading Spanish generics company, highlights the importance of diversification and internationalization in the firm’s growth strategy. He also explains the need to better value the generics market, which will, in turn, give rise to the long-term sustainability of the industry and open up…

Generics Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of…

Spain Juan Luis Fernández Balaguer, general manager of Laboratorios Combix, the Spanish affiliate of Zydus Cadila, shares the milestones achieved by the company since joining the group and its promising future as one of two European operations. Having formerly served as president of AESEG, he then goes on to offer expert…

Turkey Funda Gücer, country manager at Mylan Turkey, portrays her experience in introducing the company to the Turkish market. She provides her expert insights into current trends in the Turkish generics market and reinforces her company’s commitment to providing quality, affordable treatments.   I think that Turkey is one of the…

Spain Joachim Teubner, general manager of Aristo Pharma Iberia, a generics player, highlights the strategy that has helped the company realize rapid growth during a time in which the Spanish generic market has stagnated. Furthermore, he touches on the importance of self-manufacturing for generics companies and the future aspirations of the…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

Turkey Tuğçe Koç reveals how Onko Koçsel was able to quickly grow from an in-licenser to a production-oriented pharmaceutical company with an international reach. She also offers her take on how the Turkish healthcare sector could encourage more companies to grow and how existing companies can combat economic fluctuations.   By…

Malaysia David Ho, managing director of Hovid, introduces the success story of his family-owned company, which started at a Chinese herbal tea manufacturer and became one of the biggest local generic manufacturers in Malaysia. He also indicates his future plan to increase the company’s international presence.   We are now present…

Turkey Tahsin Yüksel, general manager of Teva Turkey, analyzes the strategic importance of pharmaceutical branding in Turkey, shares the story of Teva’s adaptation to the unique market needs, and offers his insight of what can be expected of the industry in the wake of the country’s current economic hardships.   It…

Malaysia Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company in Malaysia as well as the importance of a manager working closely with his team to achieve growth.   Malaysia…

France Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France. Bourrienne-Bautista offers her thoughts on the 8th edition of the Strategic Council of Health Industries (CSIS) and outlines a plan…